These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17189283)

  • 1. Thrombotic microangiopathy and anti-VEGF agents.
    Izzedine H; Brocheriou I; Deray G; Rixe O
    Nephrol Dial Transplant; 2007 May; 22(5):1481-2. PubMed ID: 17189283
    [No Abstract]   [Full Text] [Related]  

  • 2. VEGF inhibition and renal thrombotic microangiopathy.
    Nochy D; Lefaucheur C; Hill G
    N Engl J Med; 2008 Jul; 359(2):206; author reply 206-7. PubMed ID: 18618951
    [No Abstract]   [Full Text] [Related]  

  • 3. VEGF inhibition and renal thrombotic microangiopathy.
    Katavetin P; Katavetin P
    N Engl J Med; 2008 Jul; 359(2):205-6; author reply 206-7. PubMed ID: 18614790
    [No Abstract]   [Full Text] [Related]  

  • 4. VEGF inhibition and renal thrombotic microangiopathy.
    Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
    N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.
    Suga S; Kim YG; Joly A; Puchacz E; Kang DH; Jefferson JA; Abraham JA; Hughes J; Johnson RJ; Schreiner GF
    Kidney Int; 2001 Oct; 60(4):1297-308. PubMed ID: 11576344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF Trap for the treatment of malignant ascites.
    Becker G; Blum HE
    Lancet Oncol; 2012 Feb; 13(2):115-6. PubMed ID: 22192728
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of early renal biopsy in cyclosporin induced thrombotic microangiopathy.
    Burke GA; McGraw ME; MacIver AG
    Pediatr Nephrol; 1999 Sep; 13(7):564-6. PubMed ID: 10460501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of vascular endothelial growth factor in restenosis: the controversy continues.
    Shiojima I; Walsh K
    Circulation; 2004 Oct; 110(16):2283-6. PubMed ID: 15492329
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 11. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
    Prescrire Int; 2015 Sep; 24(163):207. PubMed ID: 26417628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells.
    Dallas NA; Fan F; Gray MJ; Van Buren G; Lim SJ; Xia L; Ellis LM
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):433-41. PubMed ID: 17786539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.
    Major JC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(3):225-6. PubMed ID: 23676221
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 17. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V; Quaggin SE
    Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF and myeloid leukemias.
    Frankel AE; Gill PS
    Leuk Res; 2004 Jul; 28(7):675-7. PubMed ID: 15158088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.